Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma

Instituto Mexicano del Seguro Social320 enrolled

Overview

Assess the impact in outcome of the use of zoledronic acid in multiple myeloma.

Assess if the use of zoledronic acid can improve outcome in patients with multiple myeloma whose are treated with cytoreductive therapy and stem cell transplant.

Study Type

OBSERVATIONAL

Enrollment

320

Conditions

Multiple Myeloma

Interventions

zoledronic acidDRUG

zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: Diagnosis of multiple myeloma No previous treatment Symptomatic High risk (ISS) or stage III ( Durie-Salmon) No severe comorbidities - Exclusion Criteria: Pregnancy HIV + Refuse treatment \-

Locations (1)

Tertiary reference oncology center

Mexico City, Mexico City, Mexico

Outcomes

Primary Outcomes

progression-free disease and overall toxicity in myeloma multiple

In patients treated with cytoreductive therapy following by stem cell transplant and that received zoledronic acid by 2 years,they were evaluable for assess antitumor effect of zoledronic acid

Time frame: 3 years

Secondary Outcomes

skeletal event

evaluate the number of skeletal events in patients with multiple myeloma that received zoledronic acid

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.